0001209191-21-068582.txt : 20211208
0001209191-21-068582.hdr.sgml : 20211208
20211208180601
ACCESSION NUMBER: 0001209191-21-068582
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211207
FILED AS OF DATE: 20211208
DATE AS OF CHANGE: 20211208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MCCLUNG BARBARA G
CENTRAL INDEX KEY: 0001231321
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40631
FILM NUMBER: 211479766
MAIL ADDRESS:
STREET 1: CARIBOU BIOCIENCES, INC.
STREET 2: 2929 7TH STREET, SUITE 105
CITY: BERKELEY
STATE: CA
ZIP: 94710
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Caribou Biosciences, Inc.
CENTRAL INDEX KEY: 0001619856
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 453728228
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2929 7TH STREET, SUITE 105
CITY: BERKELEY
STATE: CA
ZIP: 94710
BUSINESS PHONE: 510-982-6030
MAIL ADDRESS:
STREET 1: 2929 7TH STREET, SUITE 105
CITY: BERKELEY
STATE: CA
ZIP: 94710
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-12-07
0
0001619856
Caribou Biosciences, Inc.
CRBU
0001231321
MCCLUNG BARBARA G
2929 7TH STREET, SUITE 105
BERKELEY
CA
94710
0
1
0
0
Chief Legal Officer
Common Stock
2021-12-07
4
P
0
12
2.69
A
342856
D
Common Stock
2021-12-07
4
P
0
6115
2.69
A
348971
D
Option to purchase Common Stock
2.69
2021-12-07
4
X
0
12
0.00
D
2028-06-11
Common Stock
12
77
D
Option to purchase Common Stock
2.69
2021-12-07
4
X
0
6115
0.00
D
2029-09-30
Common Stock
6115
74836
D
These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below.
The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021.
The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on June 12, 2022, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on October 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
/s/ Rachel E. Haurwitz, as attorney-in-fact
2021-12-08